EA202191622A1 - STABILIZED SOLUBLE RSV F-PROTEINS BEFORE FUSION - Google Patents
STABILIZED SOLUBLE RSV F-PROTEINS BEFORE FUSIONInfo
- Publication number
- EA202191622A1 EA202191622A1 EA202191622A EA202191622A EA202191622A1 EA 202191622 A1 EA202191622 A1 EA 202191622A1 EA 202191622 A EA202191622 A EA 202191622A EA 202191622 A EA202191622 A EA 202191622A EA 202191622 A1 EA202191622 A1 EA 202191622A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- before fusion
- proteins before
- soluble rsv
- stabilized soluble
- proteins
- Prior art date
Links
- 230000004927 fusion Effects 0.000 title abstract 2
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 2
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C07K14/135—Respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
Abstract
Настоящее изобретение предусматривает стабильные F-белки респираторного синцитиального вируса (RSV) до слияния (или их фрагменты), композиции, содержащие указанные белки, и пути их применения для предупреждения и/или лечения инфекции, вызванной RSV.The present invention provides pre-fusion stable respiratory syncytial virus (RSV) F proteins (or fragments thereof), compositions containing said proteins, and ways of using them to prevent and/or treat RSV infection.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16163810 | 2016-04-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202191622A1 true EA202191622A1 (en) | 2022-01-31 |
Family
ID=55752165
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202191622A EA202191622A1 (en) | 2016-04-05 | 2017-04-04 | STABILIZED SOLUBLE RSV F-PROTEINS BEFORE FUSION |
EA201892251A EA039095B1 (en) | 2016-04-05 | 2017-04-04 | Stabilized soluble pre-fusion rsv f proteins |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201892251A EA039095B1 (en) | 2016-04-05 | 2017-04-04 | Stabilized soluble pre-fusion rsv f proteins |
Country Status (29)
Country | Link |
---|---|
US (2) | US11155583B2 (en) |
EP (2) | EP3808374A1 (en) |
JP (2) | JP7088841B2 (en) |
KR (2) | KR102506895B1 (en) |
CN (2) | CN116063551A (en) |
AU (2) | AU2017248021B2 (en) |
BR (1) | BR112018070013A2 (en) |
CA (1) | CA3018941A1 (en) |
CL (1) | CL2018002826A1 (en) |
CY (1) | CY1124019T1 (en) |
DK (1) | DK3439672T3 (en) |
EA (2) | EA202191622A1 (en) |
ES (1) | ES2858315T3 (en) |
HR (1) | HRP20210113T1 (en) |
HU (1) | HUE053027T2 (en) |
IL (2) | IL262108B2 (en) |
LT (1) | LT3439672T (en) |
MA (2) | MA43763B1 (en) |
MD (1) | MD3439672T2 (en) |
MX (2) | MX2018012094A (en) |
MY (1) | MY190320A (en) |
PE (1) | PE20190420A1 (en) |
PH (1) | PH12018501962A1 (en) |
PL (1) | PL3439672T3 (en) |
PT (1) | PT3439672T (en) |
RS (1) | RS61456B1 (en) |
SG (1) | SG11201807913XA (en) |
SI (1) | SI3439672T1 (en) |
WO (1) | WO2017174568A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX361774B (en) * | 2013-04-25 | 2018-12-17 | Janssen Vaccines & Prevention Bv | Stabilized soluble prefusion rsv f polypeptides. |
WO2015013551A1 (en) | 2013-07-25 | 2015-01-29 | Marshall Christopher Patrick | Conformationally stabilized rsv pre-fusion f proteins |
US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
WO2017005844A1 (en) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
BR112018070323A2 (en) | 2016-04-05 | 2019-01-29 | Janssen Vaccines & Prevention Bv | rsv vaccine |
AU2017248021B2 (en) * | 2016-04-05 | 2021-08-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
WO2017207480A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
BR112019020661A2 (en) | 2017-04-04 | 2020-05-05 | University Of Washington | self-assembling protein nanostructures that exhibit paramyxovirus and / or pneumovirus f proteins and their use |
AU2019228551A1 (en) | 2018-02-28 | 2020-10-15 | University Of Washington | Self-assembling nanostructure vaccines |
EP3880243A1 (en) | 2018-11-13 | 2021-09-22 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
JP2023519740A (en) | 2020-04-02 | 2023-05-12 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | Stabilized vaccine composition |
CA3188170A1 (en) | 2020-06-29 | 2022-01-06 | Janssen Vaccines & Prevention B.V. | Vaccine combination against respiratory syncytial virus infection |
WO2022175477A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv fb antigens |
WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
FR2705686B1 (en) | 1993-05-28 | 1995-08-18 | Transgene Sa | New defective adenoviruses and corresponding complementation lines. |
DE69535178T2 (en) | 1994-06-10 | 2006-12-14 | Genvec, Inc. | ADENOVER VECTOR SYSTEMS AND CELL LINES |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
ES2333425T5 (en) | 1995-06-15 | 2012-08-28 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus intended for gene therapy |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
CA2177085C (en) | 1996-04-26 | 2007-08-14 | National Research Council Of Canada | Adenovirus e1-complementing cell lines |
IL127692A0 (en) | 1996-07-01 | 1999-10-28 | Rhone Poulenc Rorer Sa | Method for producing recombinant adenovirus |
FR2751343B1 (en) | 1996-07-16 | 1998-12-18 | Transgene Sa | PROCESS FOR THE PRESERVATION OF INFECTIOUS RECOMBINANT VIRUSES, AQUEOUS VIRAL SUSPENSION, AND USE AS A MEDICAMENT |
WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
KR100503701B1 (en) | 1996-11-20 | 2005-07-26 | 인트로겐 테라페티스, 인코퍼레이티드 | An improved method for the production and purification of adenoviral vectors |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
CA2283253A1 (en) | 1997-03-04 | 1998-09-11 | Baxter International Inc. | Adenovirus e1-complementing cell lines |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
BR9908015A (en) | 1998-02-17 | 2001-04-24 | Schering Corp | Compositions comprising viruses and methods for concentrating virus preparations |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
EP1133316B1 (en) | 1998-11-16 | 2009-01-21 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
EP1816205B1 (en) | 1999-05-17 | 2011-08-10 | Crucell Holland B.V. | Recombinant Adenovirus based on serotype 48 (Ad48). |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
DE19955558C2 (en) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanent amniocyte cell line, its production and use for the production of gene transfer vectors |
AU4346101A (en) | 2000-03-07 | 2001-09-17 | Merck & Co., Inc. | Adenovirus formulations |
NZ523036A (en) | 2000-05-08 | 2004-04-30 | Davisco Foods Internat Inc | Enzymatic treatment of whey proteins for the production of antihypertensive peptides, the resulting products and treatment of hypertension in mammals |
AUPR878401A0 (en) | 2001-11-09 | 2001-12-06 | Biota Holdings Ltd | Methods for identifying or screening anti-viral agents |
EP1453536A4 (en) | 2001-12-12 | 2009-08-26 | Mayne Pharma Int Pty Ltd | Composition for the preservation of viruses |
US20030232018A1 (en) | 2002-01-18 | 2003-12-18 | Berlex Biosciences | Stabilized formulations of adenovirus |
US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
ES2310247T3 (en) | 2002-04-25 | 2009-01-01 | Crucell Holland B.V. | STABLE ADENOVIRAL VECTORS AND PROPAGATION METHODS OF THE SAME. |
SI1497438T1 (en) | 2002-04-25 | 2010-03-31 | Crucell Holland Bv | Means and methods for the production of adenovirus vectors |
ES2357366T3 (en) | 2002-05-14 | 2011-04-25 | MERCK SHARP & DOHME CORP. | ADENOVIRUS PURIFICATION PROCEDURES. |
SE0202110D0 (en) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
AU2003268210A1 (en) | 2002-08-28 | 2004-03-19 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
SE0301998D0 (en) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
CA2553541C (en) | 2004-01-23 | 2015-04-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Chimpanzee adenovirus vaccine carriers |
AU2005214090B2 (en) | 2004-02-23 | 2008-09-11 | Crucell Holland B.V. | Virus purification methods |
CN101155915B (en) | 2005-04-11 | 2013-12-04 | 克鲁塞尔荷兰公司 | Virus purification using ultrafiltration |
WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
WO2007110409A1 (en) | 2006-03-27 | 2007-10-04 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
EP2099486A2 (en) | 2006-11-30 | 2009-09-16 | Government Of The United States Of America, As Represented by the Secretary | Codon modified immunogenic compositions and methods of use |
US7901388B2 (en) | 2007-07-13 | 2011-03-08 | Bacoustics, Llc | Method of treating wounds by creating a therapeutic solution with ultrasonic waves |
AU2008340949A1 (en) | 2007-12-24 | 2009-07-02 | Glaxosmithkline Biologicals S.A. | Recombinant RSV antigens |
ES2532015T3 (en) | 2008-11-03 | 2015-03-23 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
KR101763093B1 (en) | 2009-02-02 | 2017-07-28 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Simian Adenovirus Nucleic Acid- and Amino Acid-Sequences, Vectors Containing Same, and Uses Thereof |
US9492531B2 (en) | 2009-06-24 | 2016-11-15 | Glaxosmithkline Biologicals Sa | Recombinant RSV vaccines |
MX2012000036A (en) | 2009-06-24 | 2012-02-28 | Glaxosmithkline Biolog Sa | Vaccine. |
DK3178490T3 (en) | 2009-07-15 | 2022-06-20 | Glaxosmithkline Biologicals Sa | RSV F protein compositions and methods for their preparation |
WO2011020079A1 (en) | 2009-08-13 | 2011-02-17 | Calmune Corporation | Antibodies against human respiratory syncytial virus (rsv) and methods of use |
CN102575233B (en) | 2009-10-15 | 2014-07-16 | 克鲁塞尔荷兰公司 | Process for adenovirus purification from high cell density cultures |
AU2010305765B2 (en) | 2009-10-15 | 2015-07-02 | Crucell Holland B.V. | Method for the purification of adenovirus particles |
WO2011050168A2 (en) | 2009-10-21 | 2011-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Rsv immunogens, antibodies and compositions thereof |
WO2011098592A1 (en) | 2010-02-15 | 2011-08-18 | Crucell Holland B.V. | Method for the production of ad26 adenoviral vectors |
CA3062786C (en) | 2010-07-09 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
PT2707385T (en) | 2011-05-13 | 2017-12-19 | Glaxosmithkline Biologicals Sa | Pre-fusion rsv f antigens |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
CN104379733B (en) | 2012-03-12 | 2016-01-20 | 克鲁塞尔荷兰公司 | Tool changes the recombinant adenovirus group of end |
MY169352A (en) | 2012-03-22 | 2019-03-25 | Janssen Vaccines & Prevention Bv | Vaccine against rsv |
WO2014005643A1 (en) | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
EP2970398B1 (en) | 2013-03-13 | 2024-05-08 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
US9060975B2 (en) * | 2013-03-14 | 2015-06-23 | Mucosis Bv | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
JP6462599B2 (en) * | 2013-03-15 | 2019-01-30 | シャアメン ユニバーシティ | Epitope of RSV fusion protein and antibody recognizing the epitope |
US10196438B2 (en) | 2013-04-15 | 2019-02-05 | Janssen Vaccines & Prevention B.V. | Human antibodies binding to RSV G protein |
EA035846B1 (en) | 2013-04-15 | 2020-08-20 | Янссен Вэксинс Энд Превеншн Б.В. | Human antibodies binding to rsv g protein |
MX361774B (en) * | 2013-04-25 | 2018-12-17 | Janssen Vaccines & Prevention Bv | Stabilized soluble prefusion rsv f polypeptides. |
PE20160045A1 (en) | 2013-06-17 | 2016-02-18 | Crucell Holland Bv | SOLUBLE AND STABILIZED RESPIRATORY SYNCITIAL VIRUS (RSV) PREFUSION POLYPEPTIDES F |
WO2015013551A1 (en) | 2013-07-25 | 2015-01-29 | Marshall Christopher Patrick | Conformationally stabilized rsv pre-fusion f proteins |
PL3046536T3 (en) | 2013-09-19 | 2019-06-28 | Janssen Vaccines & Prevention B.V. | Improved adenovirus formulations |
BR112018070323A2 (en) | 2016-04-05 | 2019-01-29 | Janssen Vaccines & Prevention Bv | rsv vaccine |
AU2017248021B2 (en) * | 2016-04-05 | 2021-08-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
EP3681533A1 (en) | 2017-09-15 | 2020-07-22 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against rsv |
-
2017
- 2017-04-04 AU AU2017248021A patent/AU2017248021B2/en active Active
- 2017-04-04 CA CA3018941A patent/CA3018941A1/en active Pending
- 2017-04-04 CN CN202210915265.9A patent/CN116063551A/en active Pending
- 2017-04-04 IL IL262108A patent/IL262108B2/en unknown
- 2017-04-04 CN CN201780021720.8A patent/CN109069616A/en active Pending
- 2017-04-04 EP EP20201970.9A patent/EP3808374A1/en active Pending
- 2017-04-04 US US16/091,344 patent/US11155583B2/en active Active
- 2017-04-04 MA MA43763A patent/MA43763B1/en unknown
- 2017-04-04 KR KR1020187031418A patent/KR102506895B1/en active IP Right Grant
- 2017-04-04 SI SI201730579T patent/SI3439672T1/en unknown
- 2017-04-04 MA MA052910A patent/MA52910A/en unknown
- 2017-04-04 WO PCT/EP2017/057962 patent/WO2017174568A1/en active Application Filing
- 2017-04-04 EA EA202191622A patent/EA202191622A1/en unknown
- 2017-04-04 ES ES17715692T patent/ES2858315T3/en active Active
- 2017-04-04 EP EP17715692.4A patent/EP3439672B1/en active Active
- 2017-04-04 BR BR112018070013A patent/BR112018070013A2/en unknown
- 2017-04-04 LT LTEP17715692.4T patent/LT3439672T/en unknown
- 2017-04-04 PE PE2018001917A patent/PE20190420A1/en unknown
- 2017-04-04 PL PL17715692T patent/PL3439672T3/en unknown
- 2017-04-04 SG SG11201807913XA patent/SG11201807913XA/en unknown
- 2017-04-04 JP JP2018552227A patent/JP7088841B2/en active Active
- 2017-04-04 KR KR1020227009874A patent/KR20220041966A/en not_active Application Discontinuation
- 2017-04-04 EA EA201892251A patent/EA039095B1/en unknown
- 2017-04-04 HU HUE17715692A patent/HUE053027T2/en unknown
- 2017-04-04 DK DK17715692.4T patent/DK3439672T3/en active
- 2017-04-04 MD MDE20190180T patent/MD3439672T2/en unknown
- 2017-04-04 RS RS20210212A patent/RS61456B1/en unknown
- 2017-04-04 IL IL291604A patent/IL291604B2/en unknown
- 2017-04-04 MY MYPI2018703623A patent/MY190320A/en unknown
- 2017-04-04 PT PT177156924T patent/PT3439672T/en unknown
- 2017-04-04 MX MX2018012094A patent/MX2018012094A/en unknown
-
2018
- 2018-09-12 PH PH12018501962A patent/PH12018501962A1/en unknown
- 2018-10-03 MX MX2022015257A patent/MX2022015257A/en unknown
- 2018-10-04 CL CL2018002826A patent/CL2018002826A1/en unknown
-
2021
- 2021-01-22 HR HRP20210113TT patent/HRP20210113T1/en unknown
- 2021-02-25 CY CY20211100159T patent/CY1124019T1/en unknown
- 2021-07-27 AU AU2021209185A patent/AU2021209185B2/en active Active
- 2021-10-08 US US17/450,348 patent/US20220089652A1/en active Pending
-
2022
- 2022-03-28 JP JP2022052138A patent/JP7362819B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202191622A1 (en) | STABILIZED SOLUBLE RSV F-PROTEINS BEFORE FUSION | |
EA201890235A1 (en) | STABILIZED SOLUBLE RSV F-POLYPEPTIDES TO MERGER | |
EA201592048A1 (en) | STABILIZED SOLUBLE RSV F-POLYPEPTIDES TO MERGER | |
EA201690031A1 (en) | STABILIZED SOLUBLE RSV F-POLYPEPTIDES BEFORE MERGING | |
EA201892702A1 (en) | STABILIZED RSV F-PROTEINS TO MERGER | |
EA202191355A1 (en) | STABILIZED F-PROTEINS RSV BEFORE FUSION | |
EA202091898A1 (en) | ANTIBODIES THAT NEUTRALIZE THE HUMAN IMMUNODEFICIENCY VIRUS | |
EA201791886A1 (en) | ANTI-VIRUS CONNECTIONS | |
EA201892415A1 (en) | POLYMORPHONE FORM | |
EA201592184A1 (en) | 4'-FLUOR-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES | |
EA201792561A1 (en) | ANTIBODIES AIMED ON MORPHOGENETIC BONE 9 PROTECTION (BMP9) AND METHODS OF THEIR APPLICATION | |
EA201792262A1 (en) | PIROGLUTAMAT VORTIOKSETINA | |
PH12017502356A1 (en) | Immunoglobulin single variable domain antibody against rsv prefusion f protein | |
EA201892376A1 (en) | COMBINED COMPOSITION OF THREE ANTI-VIRUS COMPOUNDS | |
MX2021004356A (en) | Formulations of anti-rsv antibodies and methods of use thereof. | |
EA202090971A1 (en) | METHODS OF APPLICATION AND COMPOSITIONS CONTAINING DULAGLUTIDE | |
EA201992054A1 (en) | CYCLIC SULFAMIDE COMPOUNDS AND WAYS OF THEIR APPLICATION | |
EA201990301A1 (en) | SUBSTITUTED PYROLYSINE AND THEIR APPLICATION |